Nadav Kidron is CEO & President at ORAMED PHARMACEUTICALS INC. (ORMP). They have made 8 open-market trades across 1 company since 2015, most recently 2026-09-24.
CIK 0001351779
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $477K since 2015, against 2 sales. Across 6 scored buys the stock is up 24.5% at ninety days, and 19.5 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 50% | 50% |
| Avg Move | -4.6% | +0.7% | +24.5% |
| Alpha | -3.4% | -1.7% | +19.5% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ORMP | BUY | 2023-03-16 | 2023-03-16 | $2.04 | $53K | -2.3% | +2.7% | +73.9% |
| ORMP | BUY | 2023-03-14 | 2023-03-15 | $2.01 | $402K | +5.4% | +9.3% | +94.6% |
| ORMP | SELL | 2021-08-09 | 2021-08-11 | $20.11 | $4.4M | -19.4% | -0.8% | +48.5% |
| ORMP | BUY | 2018-07-11 | 2018-07-12 | $5.92 | $722 | -8.7% | -17.8% | -28.2% |
| ORMP | SELL | 2018-07-10 | 2018-07-12 | $5.98 | $365 | -8.7% | -17.8% | -28.2% |
| ORMP | BUY | 2016-05-12 | 2016-05-12 | $6.95 | $7K | +18.9% | +10.5% | +7.0% |
| ORMP | BUY | 2015-05-12 | 2015-05-12 | $6.60 | $4K | -20.4% | -0.1% | -0.1% |
| ORMP | BUY | 2015-03-18 | 2015-03-20 | $3.88 | $10K | -20.4% | -0.1% | -0.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.